Option awards are generally granted with an exercise price equal to the fair value of the Company’s common stock at the date of grant.

A summary of the stock option activity for the three months ended March 31, 2025, is as follows:


	Number of Options (in thousands)	Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value (in millions)
Balance-December 31, 2024	7,233	$	2.51	2.4	$	2

Exercised	(28)	0.99

Expired	(182)	3.01
Balance-March 31, 2025	7,023	$	2.50	2.2	$	—
Exercisable-March 31, 2025	7,023	$	2.50	2.2	$	—

A summary of the RSU activity for the three months ended March 31, 2025, is as follows:


	Number of RSUs (in thousands)	Weighted- Average Grant-Date Fair Value
Unvested and outstanding-December 31, 2024	45,247	$	2.77
Granted	13,750	1.17
Vested	(5,900)	3.66
Forfeited	(7,356)	3.24
Unvested and outstanding-March 31, 2025	45,741	$	2.10

Stock-based compensation expense is allocated based on the cost center to which the award holder belongs. The following table summarizes total stock-based compensation expense by function as presented in the condensed consolidated statements of operations for the three months ended March 31, 2025 and 2024 (in millions):


	Three Months Ended March 31,
	2025		2024
General and administrative	$	9	$	16
Sales, marketing and operations	2		5
Technology and development	3		12
Total stock-based compensation expense	$	14	$	33

As of March 31, 2025, there was $81 million of unamortized stock-based compensation costs related to unvested RSUs. The unamortized compensation costs are expected to be recognized over a weighted-average period of approximately 2.0 years.